Unum racks up yet another FDA hold as it twists its way through a restructuring, looking for a fresh start with a preclinical drug

The drumbeat of bad news at Unum Therapeutics just won’t stop.

In a filing with the SEC today, the troubled biotech reported that its experimental therapy ACTR707 — used in combination with rituximab in patients with CD20+ B cell non-Hodgkin lymphoma — may have been responsible for a possible new malignancy. The FDA slapped a partial hold on the study March 4 while the agency and the biotech explore what happened to trigger the Grade 3 SAE.